In recent years the availability of several tyrosine kinase inhibitors (TKI) 
INTRODUCTION
The Src and Abl families of non-receptor protein tyrosine kinases have been extensively studied as targets for anticancer therapy because of their involvement in signaling pathways promoting tumor growth and progression [1] [2] [3] . Moreover, the presence of the constitutively active chimeric protein BCR-ABL, an oncogenic product arising from reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome) [4] , is regarded the pathogenetic characteristic of chronic myeloid leukemia (CML).
Selective inhibition of BCR-ABL autophosphorylation and phosphorylation of its substrates by tyrosine kinase inhibitors (TKI) resulted in a substantial and dramatic improvement of survival of CML patients, and has become one of the most important examples of target therapy [5] .
Nowadays, paradoxically (although luckily) treatment of CML has become more complicated, because of the availability of second and third-generation TKI, which are used as both salvage therapy and alternative simple options [6] .
Several studies have confirmed the long-term efficacy and manageable safety profile of imatinib, the first approved TKI. However, approximately 40% of patients have to switch to different treatment because of intolerance or resistance [7, 8] . Second-generation TKI have resulted in a favorable outcome for approximately half of non-responding patients after primary or secondary resistance [9, 10] . In addition, use of new TKI as initial treatment resulted in improved efficacy with evidence of an extremely good molecular response and lower progression, irrespective of features and risk at diagnosis, but with inconsistent long-term overall survival compared with imatinib [11, 12] .
Bosutinib, a second-generation dual inhibitor of Src and Abelson (Src/Abl) kinases, is currently approved in Europe and USA for treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome-positive CML previously treated with one or more TKI and for whom imatinib, nilotinib, and dasatinib are not regarded as appropriate treatment options.
The purpose of this review is to focus on efficacy and safety data for bosutinib for treatment of resistant and/or intolerant CML or for newly diagnosed CP-CML patients.
This article is based on previously conducted studies and does not include any new studies of human or animal subjects performed by any of the authors.
MECHANISM OF ACTION
Bosutinib is an orally bioavailable 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile originally identified by Boschelli, in 2001 , to act as a Src tyrosine kinase inhibitor [13] . Two years later, Golas documented potent antiproliferative and pro-apoptotic activity of bosutinib, at concentrations between 1 and 20 nM, against CML culture (K562, KU812, and Meg-01) [14] . was also identified as a novel kinase target inhibited by the drug [17] .
PHARMACOKINETIC DATA
The pharmacokinetic (PK) profile of the drug in the orally bioavailable form was extensively studied in phase I/II trials among either adult healthy volunteers of cancer patients.
Population PK analysis of three clinical studies among patients with cancer suggested that baseline characteristics (age, body weight, gender and race) did not affect the PK data.
Drug absorption was relatively slow, with a median time to peak concentration of 4-6 h and a half life t 1/2 ranging from 33 to 39 h, thus supporting a once-daily dosing regimen [18] . The effect of food was studied among 55 healthy subjects randomly assigned to receive bosutinib 200, 400, 600, or 800 mg with food or 200 or 400 mg without food, or placebo [19] .
Significant increase in bosutinib exposure was observed for maximum serum concentration (C max ), and area under the curve (AUC)
increased by 1.6-1.7-fold when taken with food, the effect being more evident at lower doses. The interaction, resulting in increased drug exposure, was explained by an increase in bosutinib solubility when taken with food [19] .
After administration of a single dose of 500 mg bosutinib, mean apparent volume of distribution for patients with CML was 6080 ± 1230 L, which correlated with extensive partitioning into tissues. Bosutinib is highly bound to human plasma proteins in vitro (94%) and ex vivo in healthy subjects (96%), and binding was not concentrationdependent. The major circulating metabolites identified in plasma were oxydechlorinated (M2) bosutinib (19% of parent exposure) and N-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib N-oxide (M6) a minor circulating metabolite. All the metabolites were inactive [20] .
For patients with CML given single oral doses of 500 mg bosutinib with food, the mean terminal phase elimination half-life was with that for administration of bosutinib alone [21] . In a cross-over trial of 24 healthy volunteers, a single dose of 500 mg bosutinib was administered alone or in combination with six daily doses of 600 mg of rifampicine, a potent CYP3A4 inducer, under fed conditions. Rifampicine decreased bosutinib C max and AUC by 86% and 94%, respectively [22] . According to these data, concurrent use of bosutinib with strong or moderate CYP3A inhibitors (and inducers) should be avoided whenever possible. Furthermore, P-glycoprotein (P-gp)
inhibitors and grapefruit or grapefruit juice should be avoided because their administration may result in increased drug plasma concentrations. In-vitro data showed no effect of bosutinib as an inducer or inhibitor of the metabolic liver enzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.
Interaction of bosutinib with gastroprotective drugs was tested in a trial with 24 healthy fasting subjects. A single 400-mg dose of bosutinib was given concurrently with repeated doses of lansoprazole 60 mg. Bosutinib C max and AUC decreased by 46% and 26%, respectively [23] . previous imatinib therapy, respectively [24] . Associations between bosutinib exposure at steady state and key efficacy endpoints from each of the two studies were also investigated.
An exposure-response relationship was identified for the incidence (but not severity) of diarrhea; a weak relationship was also observed for the incidence of rash. 
PHASE 1/2 STUDY: CLINICAL EFFICACY
In the phase 1 portion of a phase 1/2 study that enrolled imatinib-treated CML patients, the bosutinib dose of 600 mg/d was the maximum tolerated dose. Part 1 was a dose-escalation study with 3 ? 3 design with subsequent cohorts of 3-6 imatinib-resistant patients. The dose of 500 mg once-daily was selected for phase 2 of the trial; the trial was later amended to include nilotinib and dasatinib-treated patients when these drugs became commercially available.
Escalation to 600 mg daily was allowed after lack of efficacy (failure to achieve CHR by week 8 in the 400-500 mg cohorts; indeed, in the 600 mg cohort, one patient developed vomiting, rash, and nausea related to the drug.
In the second part of the trial, the median dose intensity reported was 484.9 mg/day for 
SAFETY OF PHASE 1/2 STUDY
The most common adverse side effects observed were gastrointestinal, for example diarrhea, nausea, vomiting, abdominal pain, rash, fever, fatigue and increased alanine aminotransferase.
Most frequent grade 3/4 side effects were low incidence of diarrhea, increased ALT, and rash.
Only 3% of patients experienced a pleural effusion related to the drug. Gastrointestinal side effects occurred early, and usually of low severity; transient diarrhea was managed with loperamide in 69% of cases, with temporarily interruptions in 15% of cases, or reduction of dose for 6% of patients. Forty-five percent of patients used antiemetic for nausea and 33% for vomiting. Cardiac side effects were reported for 14% of patients, the most frequent being atrial fibrillation and palpitations; two patients discontinued as a result of cardiac side effects and one died of unrelated cardiac failure. With regard to hematologic toxicity, 24% of patients experienced grade 3/4 thrombocytopenia in a median time of 21 days, whereas 17% experienced grade 3/4 neutropenia and 8% anemia (Fig. 1) . The most frequent laboratory abnormalities were elevated ALT (58% overall and 10% as grade 3/4), hypophosphatemia (43% overall and 9% as grade 3/4), and elevated lipase (28% overall and 8% as grade 3/4). Also in the advanced phase of the disease, the most common side effects were gastrointestinal with diarrhea among 85% of AP patients and among 64% of BP patients, mostly of grade 1/2. The most common serious adverse side effects reported were pneumonia AP/BP accelerated/blastic phase, BELA bosutinib efficacy and safety in newly diagnosed CML, CCyR complete cytogenetic response, CHR complete hematological response, CMR complete molecular response, IMA-I imatinib-intolerant, IMA-R imatinib-resistant, MMR major molecular response, PFS progression-free survival, NR not reported, OS overall survival among AP patients (9 patients) and pyrexia for 6 BP patients [27] ( Table 2) .
BOSUTINIB FOR NEWLY DIAGNOSED CML PATIENTS
The BELA study was a phase 3 randomized trial that compared bosutinib with imatinib for newly diagnosed CP-CML patients [30] . Five hundred and two patients were randomly assigned 1:1 to bosutinib at a dose of 500 mg per day or imatinib at 400 mg per day. Follow-up at 1 year reported CCyR, the primary endpoint of the study, of 70% for bosutinib and 68% for imatinib, without significant difference. Median time to achieve CCyR was faster with bosutinib. MMR was higher for bosutinib (41% compared with 27%
for imatinib) and CMR was also higher for bosutinib (12% versus 3% CCyR was 79% with bosutinib and 80% with imatinib, whereas MMR was 59% and 49%, respectively. Responses were durable and since the previous report at 1 year no new cases of progression were detected with bosutinib whereas another four cases were observed with imatinib [31] ( Table 1) . Fig. 1 Suggested management of the most frequent adverse side effects for patients treated with bosutinib
SAFETY OF BOSUTINIB AMONG NEWLY DIAGNOSED CP PATIENTS
A recently published update of the BELA trial reported safety analysis after more than 30 months of follow-up. In the bosutinib group gastrointestinal side effects were more frequent, for example diarrhea 70% compared with 26% in the imatinib arm and vomiting in 33% versus 16%, respectively. As in the phase 1/2 trial, elevation of alanine aminotransferase and aspartate aminotransferase was observed in the bosutinib group (33% and 28% versus 9% and 10%, respectively). Less common with bosutinib were recorded edema (7% versus 26%), musculoskeletal pain (cramp 5% versus 22%, bone pain 4% versus 11%), and neutropenia (13% v3ersus 30%). No significant difference was noted between the two groups.
Gastrointestinal events were usually transient, manageable with concomitant medications, and usually occurred during the first months of treatment. In particular, diarrhea was managed by dose modification and/or concomitant medication [33] ( Table 2) .
CARDIOVASCULAR SAFETY ANALYSIS
Retrospective analysis evaluating cardiac toxicity data from the 2 studies (BELA and study 200) has been reported. Patients were excluded at study entry if they required medications that prolong the QT interval, had a history of significant/uncontrolled cardiac disease (congestive heart failure, uncontrolled angina, or hypertension within 3 months, myocardial infarction within 12 months, (13) 28 (14) Anemia 91 (12) 86 (18) 25 (8) 22 (6) Neutropenia 49 (14) 51 (24) 13 (8) 29 (16) Diarrhea 84 (9) 85 (13) 70 (12) 25 (1) Nausea 42 (0) 51 (5) 32 (1) 36 (0) Vomiting 35 (2) 41 (9) 32 (3) 16 (0) Rash 32 (9) 41 (11) 24 (2) 19 (1) Pyrexia 27 (1) 16 (0) 18 (1) 12 (1) Abdominal pain 23 (1) 25 (2) 13 (1) 7 (\1) Fatigue 23 (1) 25 (2) 13 (1) 14 (1) Elevated AST 49 (4) 55 (7) 27 (8) 9 (3) Elevated ALT 55 (10) 66 (11) 32 (18) 8 ( In the phase 3 BELA study, discontinuations because of cardiac side effects were numerically higher for bosutinib-treated than for imatinib-treated patients (1.6% versus 0%, respectively). Reasons for discontinuation for the 4 bosutinib-treated BELA patients were pericardial effusion, right bundle branch block, congestive cardiac failure, and ECG QT prolonged.
In both bosutinib studies, few patients (2.0%; grade 3/4, 0.9%) discontinued bosutinib because of cardiac side effects. 
